Merus N.V.

Company Listings from SPi: Merus N.V.

You are here: Home >> SPi Company Listings >> Merus N.V.

 

Merus N.V.

Website:
http://

Search for other references to "merus" on SPi News

Latest Merus N.V. News

Merus to Participate in Guggenheim Healthcare Talks Idea Forum UTRECHT, Netherlands, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length huma...... 12:00 GMT Thursday 7th February 2019

Merus Announces IND Clearance for MCLA-145 UTRECHT, The Netherlands, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length...... 12:00 GMT Monday 7th January 2019

Merus Announces Financial Results for the Third Quarter 2018 and Provides Business Update UTRECHT, The Netherlands, Dec. 27, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology co...... 22:05 GMT Thursday 27th December 2018

Merus Announces Global Settlement and End to All Patent Litigation with Regeneron Pharmaceuticals UTRECHT, The Netherlands, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeut...... 21:45 GMT Thursday 20th December 2018

Merus to Present at the Jefferies 2018 London Healthcare Conference UTRECHT, The Netherlands, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeut...... 12:00 GMT Thursday 8th November 2018

Merus to Present at the Cantor Fitzgerald Global Healthcare Conference UTRECHT, The Netherlands, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeu...... 21:00 GMT Thursday 27th September 2018

Merus Strengthens Team with Key Appointments Hui Liu, Ph.D., EVP, Chief Business Officer, appointed Head of Merus U.S.Peter B. Silverman, J.D., appointed EVP, General CounselJillian Connell joins as VP, Investor Relations and...... 12:00 GMT Thursday 27th September 2018

Merus to Participate in Citi’s 13th Annual Biotech Conference UTRECHT, The Netherlands, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeut...... 12:00 GMT Thursday 30th August 2018

Merus Announces Formation of a Scientific Advisory Board UTRECHT, The Netherlands, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeut...... 12:00 GMT Wednesday 22nd August 2018

Merus Announces Financial Results for the Second Quarter 2018 & Mid-year Operating Results UTRECHT, The Netherlands, Aug. 10, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology com...... 13:35 GMT Friday 10th August 2018

Buy Merus N.V.
Market Reports
from SPi

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us